Peptide Based Metabolic Disorders Therapeutics Market Outlook 2025 – Insights for Executive and Strategic Planning
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Fast Is The Peptide Based Metabolic Disorders Therapeutics Market Expected to Grow Between 2025 And 2029?#_x000D_
The market for peptide-based therapies for metabolic disorders has seen swift expansion in the recent past. From $29.89 billion in 2024, it is predicted to reach $34.4 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors contributing to this historical growth include a rise in metabolic disorders, enhancements in peptide synthesis techniques, increased healthcare spending, an aging population, growth in the biopharmaceutical sector, regulatory sanctions for novel therapies, and growing consciousness regarding personalized medicine._x000D_
_x000D_
#What Growth Rate Is Anticipated for the Peptide Based Metabolic Disorders Therapeutics Market in the Coming Years?#_x000D_
The market for peptide-based metabolic disorder treatments is projected to experience a surge in size in the coming years. It is predicted to expand to a market value of $59.85 billion by 2029, with a compound annual growth rate (CAGR) of 14.8%. This projected expansion for the forecast period can be ascribed to factors such as the creation of new peptide analogs, an increase in R&D investments in metabolic disorders, the use of precision medicine methods, growth of developing markets, drug development collaborations and partnerships, improvements in delivery technologies, and a focus on therapies centred around the patient. Key trends expected during the forecast period include the use of artificial intelligence in drug discovery, the increase in tailored therapies, the application of CRISPR/Cas9 in genetic treatments, the incorporation of wearable devices in patient monitoring, the creation of oral peptide formulations, the growth of digital therapeutics in managing diseases, and the wider scope of biobanking for individualised treatment._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=16764&type=smp_x000D_
_x000D_
#Who Are the Leading Companies in the Peptide Based Metabolic Disorders Therapeutics Market?#_x000D_
Major companies operating in the peptide based metabolic disorders therapeutics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Eli Lilly Company, Amgen Inc., Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Jazz Pharmaceuticals plc, Ipsen S.A, BioMarin Pharmaceutical Inc., Amarin Corporation plc, PolyPeptide Group_x000D_
_x000D_
#What Are the Key Drivers of the Peptide Based Metabolic Disorders Therapeutics Market?#_x000D_
The escalating incidence of obesity is anticipated to boost the expansion of the peptide-based metabolic disorders therapeutic market in the future. Characterized by excessive accumulation of body fat posing a threat to health, obesity is a medical problem. Lifestyle habits such as physical inactivity, unhealthy eating patterns, genetic susceptibility and environmental factors that endorse high-calorie diets contribute to the rising obesity cases. Therapies centred on peptide-based metabolic disorders target conditions like obesity by deploying peptides to regulate metabolic activities, amplify insulin receptivity and manage appetite. This method enhances patient health results and lessens the long-term health dangers linked to these persistent disorders. For example, in April 2024, The British Diabetic Association, a UK healthcare professional and research charity, reported that 4.4 million people in the UK live with diabetes, and approximately another 1.2 million may have type 2 diabetes that remains undiagnosed. The 2022-23 registration numbers represent a growth of 167,822 from 2021-22. Hence, the escalating rate of obesity is propelling the peptide-based metabolic disorder therapeutics market._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=16764&type=smp_x000D_
_x000D_
#What Are the Key Market Segments in the Peptide Based Metabolic Disorders Therapeutics Industry?#_x000D_
The peptide based metabolic disorders therapeutics market covered in this report is segmented –_x000D_
_x000D_
1) By Drug Type: Liraglutide, Exenatide, Other Drug Type_x000D_
2) By Application: Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Other Applications_x000D_
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies_x000D_
_x000D_
Subsegments:_x000D_
1) By Liraglutide: Brand: Saxenda, Brand: Victoza, Generic Liraglutide, Liraglutide For Type 2 Diabetes, Liraglutide For Obesity_x000D_
2) By Exenatide: Brand: Byetta, Brand: Bydureon, Exenatide For Type 2 Diabetes, Extended-Release Exenatide, Generic Exenatide_x000D_
3) By Other Drug Type: Semaglutide, Dulaglutide, Albiglutide, Lixisenatide, GLP-1 Receptor Agonists, Pramlintide, Other Peptide-Based Drugs For Metabolic Disorders_x000D_
_x000D_
#What Are the Latest Trends in the Peptide Based Metabolic Disorders Therapeutics Market?#_x000D_
Leading companies in the peptide-based metabolic disorders therapeutics market are introducing innovative peptide-based treatments, which include anti-diabetic biosimilars, to fulfill unaddressed healthcare needs and increase treatment choices for patients. Therapeutic drugs that impersonate existing peptide-based treatments for diabetes are known as peptide-based anti-diabetic biosimilars. They provide similar effectiveness and safety as the existing medications while potentially reducing the cost of treatment due to competitive pricing. To illustrate, in January 2024, Glenmark Pharmaceuticals Ltd., a pharmaceutical company from India, introduced a biosimilar named Lirafit in India. It is a version of the widely used anti-diabetic drug Liraglutide. It is a part of the group of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). These drugs imitate the function of the naturally happenning GLP-1 hormone, which is essential for controlling blood sugar levels. Clinical trials have been conducted on this biosimilar, which have proved its efficiency in reducing blood sugar levels, helping in weight loss, and improving cardiovascular safety. These aspects are essential for managing diabetes and related health issues like obesity and cardiovascular diseases._x000D_
_x000D_
#Access The Full Report Here:#_x000D_
_x000D_
#What Are the Key Regional Markets in the Peptide Based Metabolic Disorders Therapeutics Industry?#_x000D_
North America was the largest region in the peptide based metabolic disorders therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide based metabolic disorders therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Purchase The Full Report Today:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16764_x000D_
_x000D_
#This Report Delivers Insight On: #_x000D_
1. How big is the peptide based metabolic disorders therapeutics market, and how is it changing globally?_x000D_
2. Who are the major companies in the peptide based metabolic disorders therapeutics market, and how are they performing?_x000D_
3. What are the key opportunities and risks in the peptide based metabolic disorders therapeutics market right now?_x000D_
4. Which products or customer segments are growing the most in the peptide based metabolic disorders therapeutics market?_x000D_
5. What factors are helping or slowing down the growth of the peptide based metabolic disorders therapeutics market?_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 2071930708_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
